Fig 1.
Study flow diagram.
Table 1.
Mean days of symptoms prior to ETU arrival for all patients and for individual subgroups.
Fig 2.
Kaplan-Meier survival analysis by symptom day for EBOV positive patients.
Fig 3.
A. Kaplan-Meier survival analysis by day of illness for EBOV positive patients disaggregated by sex. B. Kaplan-Meier survival analysis by day of illness for EBOV positive patients disaggregated by age. *Variables have been abbreviated: Abdominal Pain = “Abd Pain”; Nausea/Vomiting = “Vomiting”; Myalgias/Arthralgias = “Myalgias”; Conjunctivitis = “Red Eyes”.
Table 2.
Baseline demographics and mortality risk by demographic subgroup for EBOV positive patients with known symptom onset date.
Fig 4.
A. Signs/Symptoms at triage for all EBOV positive patients (n = 470)*. B. Signs/Symptoms over length of illness for all EBOV positive patients (n = 422). *Variables have been combined: Myalgias/Arthralgias = "Bone Pain", "Bone and Muscle Pain" and "Joint Pain"; Nausea/Vomiting = "Nausea" and "Vomiting"; Dysphagia = "Swallowing Problems" and "Sore Throat"; Conjunctivitis = "Red Injected Eyes" and "Conjunctivitis" Variables have been abbreviated: Abdominal Pain = “Abd Pain”; Nausea/Vomiting = “Vomiting”; Myalgias/Arthralgias = “Myalgias”; Conjunctivitis = “Red Eyes”.
Fig 5.
(A-D). Symptoms by day of illness for surviving EBOV positive patients (E-H) symptoms by day of illness for non-surviving EBOV positive patients. * Numbers along the x-axis indicate the number of patients providing data for that day. Variables have been abbreviated: Abdominal Pain = “Abd Pain”; Nausea/Vomiting = “Vomiting”; Myalgias/Arthralgias = “Myalgias”; Conjunctivitis = “Red Eyes”.
Table 3.
Multivariable regression model for mortality based on signs/symptoms present at any time in the first week of illness and signs/symptoms present at any time over the total length of illness*.
Fig 6.
CT values by day of illness and final outcome for EBOV positive patients.
*Numbers along x-axis indicate the number of patients providing data for that day.
Table 4.
Initial cycle threshold (CT) values and mean CT values over entire length of illness for all EBOV positive patients and for individual demographic subgroups.